Dimitrios Papakonstantinou1, Vasileios Vardas1, Despoina M. Varouhaki2, Aikaterini Kotzamouratoglou1, Karolina Mangani1, Julia A. Ju3, Catherine Alix-Panabières4,5,6, Stuart S. Martin3, Constantinos M. Athanassopoulos2, Galatea Kallergi1,*
Oncology Research, Vol.34, No.10, 2026, DOI:10.32604/or.2026.085665
- 14 September 2026
Abstract Objectives: Combretastatin A-4 (CA-4) is a microtubule-disrupting agent with established anti-tumor properties. This study aimed to evaluate the effects of CA-4 on key metastatic traits of cancer cells, including migration, clonogenic potential, cytoskeletal protein expression, and microtentacle (McTN) formation, using multiple cancer cell models, including the colon patient-derived circulating tumor cell line CTC-MCC-41. Methods: H1299 (non-small cell lung cancer), MDA-MB-231 (triple-negative breast cancer), HT-29 (colorectal cancer), and CTC-MCC-41 (derived from the blood of a colon cancer patient) cells were treated with CA-4 (10 μM) for 24 and 48 h. Colony formation was assessed with a clonogenic… More >
Graphic Abstract